Beyond Medical Technologies Inc (DOCT) AI Stock Analysis

• Market Cap: C$14.62M
• Dividend Yield: N/A
• Average Volume (3M): 87.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: N/A
• EPS Growth: -63.69%
• Country: CA
• Employees: N/A
• Sector: Industrials
• Sector Strength: 72
• Industry: Industrial - Pollution & Treatment Controls
• EPS (TTM): -0.06
• Shares Outstanding: 32,493,960
• 10 Day Avg. Volume: 40,470
• 30 Day Avg. Volume: 87,619
• PEG Ratio: 20.13
• Price to Book (P/B): -0.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.52
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

The overall stock score for Beyond Medical Technologies Inc is significantly impacted by its critical financial health, characterized by zero revenue and negative profitability. While technical indicators show short-term positive momentum, the overbought conditions and poor valuation metrics suggest caution. Immediate strategic changes are necessary for financial recovery and sustainable growth.

Beyond Medical Technologies Inc Business Overview & Revenue Model

Company Description

Beyond Medical Technologies Inc (DOCT) is a healthcare technology company specializing in innovative medical solutions and devices. The company operates in the biotechnology and medical device sectors, focusing on the development and distribution of products that enhance patient care and streamline healthcare processes. Its core offerings include advanced diagnostic tools, telemedicine platforms, and wearable health monitoring devices.

How the Company Makes Money

Beyond Medical Technologies Inc generates revenue through the sale of its proprietary medical devices and technology solutions to healthcare providers, hospitals, and clinics. The company also monetizes its telemedicine platforms through subscription models and partnerships with healthcare institutions. Additionally, Beyond Medical Technologies Inc engages in strategic collaborations with pharmaceutical companies and research institutions to co-develop and license new technologies, contributing to its revenue streams.

Beyond Medical Technologies Inc Financial Statement Overview

Summary

Beyond Medical Technologies Inc faces severe financial challenges with zero revenue, negative profit margins, and high leverage risks. The financial statements indicate a critical need for strategic restructuring or pivoting to achieve financial stability and operational viability.

Income Statement

Beyond Medical Technologies Inc has consistently reported zero revenue in recent periods, which is a significant concern. The company shows a downward trend in profitability with negative EBIT and net income, indicating ongoing operational challenges. The lack of revenue growth and negative profit margins highlight severe difficulties in achieving sustainable operations.

Balance Sheet

The balance sheet reveals high leverage, with a negative stockholders' equity indicating significant liabilities exceeding assets. The debt-to-equity ratio is incalculable due to negative equity, which is a critical risk factor. The equity ratio is also concerning, showing negative equity relative to assets, highlighting financial instability and potential solvency issues.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating that the company is not generating sufficient cash from its operations to sustain its activities. The operating cash flow to net income ratio is negative due to continuous losses, underscoring financial distress. The inflow from financing activities suggests reliance on external funding to maintain liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	943.42K	208.66K
Gross Profit	0.00	0.00	0.00	0.00	-250.00K	-73.24K
EBITDA	-1.94M	-365.88K	-37.96K	-773.00K	-1.34M	-6.35M
Net Income	-1.99M	-285.00	-596.00K	-1.40M	-2.91M	-6.52M
Balance Sheet
Total Assets	3.19M	13.80K	95.64K	608.18K	1.95M	1.84M
Cash, Cash Equivalents and Short-Term Investments	161.84K	13.22K	64.14K	536.75K	1.43M	624.21K
Total Debt	1.05M	60.00K	30.00K	0.00	85.09K	165.01K
Total Liabilities	3.47M	634.46K	430.35K	346.94K	413.28K	361.85K
Stockholders Equity	-277.97K	-620.66K	-334.72K	261.25K	1.54M	1.48M
Cash Flow
Free Cash Flow	-362.74K	-109.77K	-527.04K	-894.01K	-1.47M	-2.07M
Operating Cash Flow	-362.74K	-109.77K	-527.04K	-894.01K	-1.40M	-1.83M
Investing Cash Flow	-2.99M	0.00	0.00	0.00	-467.99K	-260.27K
Financing Cash Flow	3.47M	30.00K	30.00K	0.00	2.67M	-65.96K

Beyond Medical Technologies Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOCT, the sentiment is Negative. The current price of 0.45 is below the 20-day moving average (MA) of 0.59, below the 50-day MA of 0.58, and above the 200-day MA of 0.36, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 32.81 is Neutral, neither overbought nor oversold. The STOCH value of 30.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DOCT.

Beyond Medical Technologies Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
APL	50 Neutral	C$3.77M	13.54	-1.36%	52.94%	―	-127.38%
WATR	47 Neutral	C$6.16M	―	-1238.40%	―	-72.45%	-987.50%
RGEN	47 Neutral	C$3.45M	―	―	―	―	―
ATMO	45 Neutral	C$475.25K	―	18.75%	―	-100.00%	5.30%
SAY	43 Neutral	C$3.74M	―	―	―	17.30%	-200.00%
DOCT	34 Underperform	C$14.62M	―	74.38%	―	―	-63.69%